Innovation Leads the Future: The 2025 China Vaccine Academic Conference Concludes Successfully, with Bio-Thera Solutions Showcasing Several Flagship Products
Release time:
2025-11-19
From November 14 to 16, 2025, the inaugural Academic Conference and Exhibition of the China Vaccine Industry Association was successfully held in Xiamen. The event brought together more than 1,800 delegates from government agencies, research institutes, universities, and domestic and international vaccine companies, with over 130 leading experts sharing cutting-edge advances in vaccine R&D and disease prevention and control. Changchun Beacon Biotechnology Co., Ltd. (hereinafter referred to as “Beacon Bio”), an innovative biopharmaceutical company dedicated to the prevention and control of infectious diseases, was invited to attend and showcased its latest developments in a focused presentation. Registered trademark Live attenuated varicella vaccine, Ganwu Registered trademark Lyophilized live attenuated influenza nasal spray vaccine, Ganwei Registered trademark Three flagship products: live attenuated shingles vaccine.
At this exhibition, Bio-Thera Solutions is showcasing its latest approved product—Ganwu. Registered trademark The intranasal live attenuated influenza vaccine (liquid formulation) has garnered significant attention. Having completed a formulation upgrade and received approval from the National Medical Products Administration for market release, this vaccine has transitioned from a lyophilized to a ready-to-use liquid form, making it currently the only influenza vaccine in China administered via intranasal spray. This innovative design effectively alleviates the pain and vaccination-related anxiety associated with traditional injection, making it particularly suitable for children and adolescents and helping to enhance vaccination willingness and adherence. The vaccine is also slated to be launched on the market soon, with vaccination programs set to commence, thereby providing a powerful new tool for the seasonal prevention and control of influenza.
In addition to showcasing its products, Bio-Thera Solutions actively engaged in academic exchanges at multiple conference sessions. On November 15, Jiang Chunlai, General Manager of Bio-Thera Solutions and Professor at the School of Life Sciences of Jilin University, delivered a keynote address at the Annual Academic Conference of the Vaccine Basic Research Professional Committee on “Progress in the Development of Therapeutic Tumor-Associated Antigen mRNA Vaccines.” He shared the latest advances in mRNA technology and cancer immunotherapy, sparking extensive discussion among the attending experts and scholars.
The “Annual Academic Conference on the Prevention and Control of Varicella and Herpes Zoster,” held on the same day, emerged as another major highlight of the conference. Experts from various fields jointly examined the current status and effectiveness of vaccination among key populations for varicella and herpes zoster, unanimously agreeing that promoting adult vaccination and deepening the integration of medical care and disease prevention are critical strategies for addressing current challenges and reducing the overall disease burden on society.
Xu Songtao, a researcher at the Institute for Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, delivered a special report titled “Shingles: Preventive Measures for Everyone—From Disease Characteristics to Integrated Medical–Preventive Practices.” The report systematically outlined the disease burden, epidemiological features, and prevention and control strategies associated with the varicella–zoster virus, with a particular focus on practical approaches for advancing “integration of medical care and prevention” within the current healthcare system. The report highlighted that shingles is not only a common infectious disease among middle-aged and older adults but is also closely linked to serious complications such as stroke and dementia. It emphasized that, guided by the Healthy China 2030 initiative and the 14th Five-Year Plan for Healthy Aging, vaccination—as a key component of integrated medical–preventive care—should be incorporated throughout the entire life course, covering children, adults, older adults, and other vulnerable populations. Strengthening the adult vaccination service delivery system, improving the infrastructure of vaccination clinics, and enhancing public awareness of vaccine-preventable diseases such as shingles are essential strategies for building a robust public health system and achieving the goal of “preventive measures for everyone.”
This year’s Academic Annual Conference of the China Vaccine Industry Association has not only established a high-level platform for exchange among industry experts and enterprises, but also highlighted the robust R&D capabilities and relentless pursuit of innovation within China’s vaccine industry by showcasing a wide array of cutting-edge innovations from various companies. Looking ahead, domestic vaccine manufacturers—led by Bio-Thera Solutions—will continue to leverage technological innovation and solid R&D efforts to actively align with the national policies of “Healthy China” and “Integration of Medical Care and Disease Prevention,” thereby providing more diverse and higher-quality solutions to address public health challenges and strengthen the population-wide immunity barrier. In doing so, they will continue to contribute to the consolidation of China’s immunization program and the broader public health protection network.
Keywords:
Recommended News